Full-Time

Associate Director

Research Technology & Scientific Computing

Posted on 9/10/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$169.2k - $253k/yr

+ Incentive opportunity

Boston, MA, USA

Hybrid

Based in the Boston area with regular in-person engagement; up to 10% travel may be required.

Bachelor's, Master's

Category
IT Operations
Required Skills
LLM
Python
High Performance Computing (HPC)
R
Infrastructure as Code (IaC)
AWS
Observability
DevOps
Linux/Unix
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Computer Science, Information Technology, Life Sciences, Engineering, or a related field.
  • Eight or more years of progressive experience in Research IT, scientific computing, laboratory technology, platform leadership, infrastructure, or related technology roles in biotechnology, pharmaceuticals, or another research-intensive environment.
  • Ability to understand scientific workflows and translate them into practical, scalable, supportable technology capabilities and service experiences.
  • Experience leading across strategy, delivery, operations, service improvement, and stakeholder engagement in a complex, matrixed environment.
  • Working knowledge of wet-lab technology, scientific applications, Linux, cloud and on-premises infrastructure, research data flows, and instrument connectivity.
  • Strong relationship leadership and the ability to influence scientists, R&D leaders, technology teams, cybersecurity, compliance partners, vendors, and senior stakeholders.
  • Judgment and communication skills that make complex technical, operational, and investment choices understandable and decision-ready.
Responsibilities
  • Partner with scientists, laboratory teams, and research leaders to ensure technology enables discovery rather than creates friction.
  • Understand critical workflows and improve how researchers compute, collaborate, access data, use applications, and operate laboratory environments.
  • Translate scientific priorities and emerging opportunities into an integrated roadmap for laboratory technology, research applications, scientific computing, cloud and on-premises services, data flows, and supporting infrastructure.
  • Balance speed and innovation with security, compliance, resilience, cost, supportability, and long-term platform health.
  • Bring together researchers, IT business partners, architecture, platform engineering, operations, cybersecurity, Data & AI, vendors, and service providers to deliver complete outcomes.
  • Resolve cross-platform dependencies early and ensure new capabilities are usable, observable, supportable, recoverable, and ready for adoption.
  • Use stakeholder personas, journeys, feedback, and service measures to identify and remove friction across organizational and technology boundaries.
  • Measure service health through technical performance, experience, adoption, and research impact, not component availability alone.
  • Lead the lifecycle, reliability, service health, supplier performance, and continual improvement of Research Technology capabilities.
  • Establish clear ownership, support models, operational readiness, knowledge, communications, training, and early-life support for new and changing services.
  • Partner with Data & AI and other enterprise technology teams to influence the adoption of emerging AI capabilities.
  • Ensure research, scientific computing, and laboratory requirements are reflected in enterprise roadmaps and delivery plans.
  • Create reusable approaches for platform roadmaps, service ownership, stakeholder experience, adoption, and cross-platform delivery across Infrastructure & Operations.
  • Represent research requirements in enterprise initiatives involving AI, scientific computing, data platforms, and emerging technology capabilities.
  • Shape technology roadmaps, capabilities, and measurable outcomes for research workflows across Jnana Therapeutics, OAPI, and OPDC.
Desired Qualifications
  • Experience with computational chemistry or biology, high-performance or high-throughput computing, and platforms such as Benchling, CDD Vault, Posit Connect, or similar technologies.
  • Experience with AWS, automation, DevOps, infrastructure as code, R, Python, analytics, metadata, integrations, or AI-enabled research and support capabilities.
  • Experience applying personas, journeys, service design, product or platform management, experience measures, service-level objectives, or adoption practices.
  • Experience supporting regulated, validated, or research-critical environments and designing for resilience, disaster recovery, and business continuity.
  • For Director-level consideration, demonstrated ownership of a broader platform or service portfolio, enterprise influence, and leadership across multiple teams, providers, or major outcomes.
  • Experience evaluating, deploying, or supporting enterprise AI solutions and AI-enabled workflows, preferably including large language model platforms, AI-assisted development tools, agentic capabilities, or scientific-research use cases.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.